Patents by Inventor Selva Sukumar
Selva Sukumar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8669105Abstract: The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.Type: GrantFiled: June 23, 2011Date of Patent: March 11, 2014Assignees: Sanofi Pasteur Vaxdesign Corp., Virginia Commonwealth UniversityInventors: Selva Sukumar, Mohey Eldin M. El Shikh, John G. Tew, Guzman Sanchez-Schmitz, Donald Drake, III, Luis Mosquera, Conan Li, Anatoly M. Kachurin, Russell Higbee, Heather Fahlenkamp, Eric Mishkin, William L. Warren
-
Patent number: 8247226Abstract: The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.Type: GrantFiled: June 23, 2011Date of Patent: August 21, 2012Assignee: Sanofi Pasteur Vaxdesign Corp.Inventors: Selva Sukumar, Mohey Eldin M. El Shikh, John G. Tew, Guzman Sanchez-Schmitz, Donald Drake, III, Luis Mosquera, Conan Li, Anatoly M. Kachurin, Russell Higbee, Heather Fahlenkamp, Eric Mishkin, William L. Warren
-
Publication number: 20110269176Abstract: The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.Type: ApplicationFiled: June 23, 2011Publication date: November 3, 2011Applicant: SANOFI PASTEUR VAXDESIGN CORPORATIONInventors: Selva SUKUMAR, Mohey Eldin M. EL SHIKH, John G. TEW, Guzman SANCHEZ-SCHMITZ, Donald DRAKE, III, Luis MOSQUERA, Eric MISHKIN, Anatoly M. KACHURIN, Russell HIGBEE, Conan LI, William L. WARREN, Heather FAHLENKAMP
-
Publication number: 20110250620Abstract: The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.Type: ApplicationFiled: June 23, 2011Publication date: October 13, 2011Applicant: SANOFI PASTEUR VAXDESIGN CORPORATIONInventors: Selva SUKUMAR, Mohey Eldin M. EL SHIKH, John G. TEW, Guzman SANCHEZ-SCHMITZ, Donald DRAKE, III, Luis MOSQUERA, Eric MISHKIN, Anatoly M. KACHURIN, Russell HIGBEE, Conan LI, William L. WARREN, Heather FAHLENKAMP
-
Patent number: 8003387Abstract: The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.Type: GrantFiled: December 21, 2006Date of Patent: August 23, 2011Assignee: Sanofi Pasteur Vaxdesign Corp.Inventors: Selva Sukumar, Mohey Eldin M. El Shikh, John G. Tew, Guzman Sanchez-Schmitz, Donald Drake, III, Luis Mosquera, Eric Mishkin, Anatoly M. Kachurin, Russell Higbee, Conan Li, William L. Warren, Heather Fahlenkamp
-
Patent number: 8003385Abstract: The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.Type: GrantFiled: February 17, 2010Date of Patent: August 23, 2011Assignee: Sanofi Pasteur Vax Design Corp.Inventors: Selva Sukumar, Mohey Eldin M. El Shikh, John G. Tew, Guzman Sanchez-Schmitz, Donald Drake, III, Luis Mosquera, Conan Li, Anatoly M. Kachurin, Russell Higbee, Heather Fahlenkamp, Eric Mishkin, William L. Warren
-
Publication number: 20100184148Abstract: The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.Type: ApplicationFiled: February 17, 2010Publication date: July 22, 2010Applicant: VAXDESIGN CORPORATIONInventors: Selva SUKUMAR, Mohey Eldin M. EL SHIKH, John G. TEW, Guzman SANCHEZ-SCHMITZ, Donald DRAKE, III, Luis MOSQUERA, Eric MISHKIN, Anatoly M. KACHURIN, Russell HIGBEE, Conan LI, William L. WARREN, Heather FAHLENKAMP
-
Publication number: 20070218054Abstract: The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.Type: ApplicationFiled: December 21, 2006Publication date: September 20, 2007Inventors: Selva Sukumar, Mohey Eldin El Shikh, John Tew, Guzman Sanchez-Schmitz, Donald Drake, Luis Mosquera, Eric Mishkin, Anatoly Kachurin, Russell Higbee, Conan Li, William Warren, Heather Fahlenkamp